Advertisement
UK markets open in 6 hours 57 minutes

  • NIKKEI 225

    37,961.80
    0.00 (0.00%)
     

  • HANG SENG

    16,251.84
    +2.87 (+0.02%)
     

  • CRUDE OIL

    82.74
    +0.05 (+0.06%)
     

  • GOLD FUTURES

    2,382.50
    -5.90 (-0.25%)
     

  • DOW

    37,753.31
    -45.66 (-0.12%)
     

  • Bitcoin GBP

    49,124.09
    -2,068.34 (-4.04%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • NASDAQ Composite

    15,683.37
    -181.88 (-1.15%)
     

  • UK FTSE All Share

    4,273.02
    +12.61 (+0.30%)
     
Money:

5 ways to get help with childcare costs

Childcare is eye-wateringly expensive, here are some ways to save money

Barclays Sticks to Their Hold Rating for Halozyme Therapeutics

Investing.com
·1-min read


Barclays (LON:BARC) analyst Gena Wang maintained a Hold rating on Halozyme (NASDAQ:HALO) Therapeutics on Tuesday, setting a price target of $21, which is approximately 15.39% below the present share price of $24.82.

Wang expects Halozyme Therapeutics to post earnings per share (EPS) of -$0.24 for the second quarter of 2020.

The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Halozyme, with an average price target of $26.86.
The analysts price targets range from a high of $39 to a low of $13.

In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $53.67 million and a net profit of -$32.06 million. The company's market cap is $3.27 billion.

ADVERTISEMENT

According to TipRanks.com, Barclays analyst Gena Wang is a 5-star analyst with an average return of 20.1% and a 55.2% success rate.

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.